Corcept Therapeutics (CORT) Depreciation & Amortization (CF) (2010 - 2026)

Corcept Therapeutics has disclosed Depreciation & Amortization (CF) across 17 years of filings, most recently posting $598000.0 for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $598000.0, up 29.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 million (up 13.02% YoY), and the FY2025 annual result was $1.1 million, up 44.53% from the prior year.
• Depreciation & Amortization (CF) came in at $598000.0 for Q1 2026 at Corcept Therapeutics, up from $289000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $660000.0 in Q4 2022 to a low of $76000.0 in Q2 2024.
• The 5-year median for Depreciation & Amortization (CF) is $281000.0 (2024), against an average of $284882.4.
• Across the five-year window, Depreciation & Amortization (CF) sank 94.77% in 2022 and surged 285.0% in 2025, its largest moves.
• Corcept Therapeutics' Depreciation & Amortization (CF) stood at $660000.0 in 2022, then sank by 67.58% to $214000.0 in 2023, then surged by 31.31% to $281000.0 in 2024, then increased by 2.85% to $289000.0 in 2025, then soared by 106.92% to $598000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $598000.0 (Q1 2026), $289000.0 (Q4 2025), and $289000.0 (Q3 2025), per Business Quant data.